What is Investigational Device Exemption?

An FDA regulatory authorization allowing a medical device to be used in clinical studies to collect safety and effectiveness data, before the device receives FDA approval or clearance.

What category does Investigational Device Exemption belong to in BCI?

Investigational Device Exemption is a Regulatory concept in brain-computer interface science.

Investigational Device Exemption — BCI Glossary

An Investigational Device Exemption (IDE) is a regulatory mechanism administered by the U.S. Food and Drug Administration (FDA) that allows medical devices not yet approved for commercial sale to be used in clinical investigations. For BCI companies, obtaining an IDE is typically the critical regulatory milestone between preclinical animal studies and first-in-human trials.

IDE Requirements

To obtain an IDE, a sponsor (company or institution) must submit an IDE application to FDA demonstrating:

Preclinical evidence: Animal studies showing the device is reasonably safe for human use (biocompatibility, bench testing, animal efficacy data)
Device description: Complete technical specifications, manufacturing information, and quality controls
Investigational plan: The proposed clinical protocol, including patient eligibility criteria, primary endpoints, follow-up duration, and statistical analysis plan
Risk-benefit analysis: Analysis of risks to subjects balanced against the potential benefit to patients and to society through knowledge gained
Informed consent: Documentation of the consent process for research participants
IRB approval: Review and approval by an Institutional Review Board at each clinical site

Significant Risk vs. Non-Significant Risk

IDE requirements differ based on device risk classification:

Significant risk (SR) devices: Implantable, life-sustaining, or devices presenting a potential for serious risk (all invasive BCI implants). Require full FDA IDE application and approval before initiating trials.
Non-significant risk (NSR) devices: Lower risk devices (most consumer EEG, etc.) may be investigated under abbreviated IDE requirements with IRB approval only.

IDE in the BCI Field

All major invasive BCI clinical trials operate under FDA-approved IDEs:

Neuralink: IDE approved May 2023 for the PRIME study of the N1 implant
Synchron: IDE approved July 2021 for the SWITCH US trial of the Stentrode
Precision Neuroscience: IDE for PATTERN I intraoperative study
BrainGate: Multiple successive IDEs covering BrainGate2 since 2009

IDE approval does not mean the device is approved for commercial use — it only authorizes use in the specific clinical investigation. After collecting IDE clinical data, companies typically pursue a Premarket Approval (PMA) application or De Novo submission for commercial authorization.